MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 314259 | Name: Edoxaban tosylate monohydrate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Edoxaban is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.

Chemical Structure

Edoxaban tosylate monohydrate
Edoxaban tosylate monohydrate
CAS#1229194-11-9 (tosylate hydrate)

Theoretical Analysis

MedKoo Cat#: 314259

Name: Edoxaban tosylate monohydrate

CAS#: 1229194-11-9 (tosylate hydrate)

Chemical Formula: C31H40ClN7O8S2

Exact Mass: 0.0000

Molecular Weight: 738.27

Elemental Analysis: C, 50.43; H, 5.46; Cl, 4.80; N, 13.28; O, 17.34; S, 8.69

Price and Availability

Size Price Availability Quantity
50mg USD 150.00 Ready to ship
100mg USD 225.00 Ready to ship
200mg USD 385.00 Ready to ship
500mg USD 750.00 Ready to ship
1g USD 1,250.00 Ready to ship
2g USD 2,050.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1229194-11-9 (tosylate hydrate) 480449-71-6 (tosylate) 480448-29-1 (HCl) 480449-70-5 (free base)
Synonym
DU-176; DU 176; DU176; DU176b; DU-176b; DU 176b; Edoxaban; Edoxaban tosylate monohydrate, trade name Lixiana; Savaysa;
IUPAC/Chemical Name
N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide 4-methylbenzenesulfonate hydrate
InChi Key
PSMMNJNZVZZNOI-SJILXJHISA-N
InChi Code
InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1
SMILES Code
O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.CC5=CC=C(S(=O)(O)=O)C=C5.[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 1229194-11-9 (Edoxaban tosylate hydrate); 480449-70-5 (Edoxaban free base).
Biological target:
Edoxaban tosylate monohydrate (DU-176b monohydrate) is a factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
In vitro activity:
Edoxaban exhibited a dose-dependent increase in anti-FXa activity; additional dilutions with normal plasma were required for edoxaban concentrations greater than 0.2 μg/mL (Fig. 4a). An assay specific for direct FXa inhibitors that is unaffected by the presence of heparin (Hyphen BioMed method) showed a concentration-dependent inhibition of OD405 by edoxaban, confirming a direct inhibitory effect on FXa activity (Fig. 4b). Reference: Thromb Res. 2012 Apr;129(4):e77-82. https://pubmed.ncbi.nlm.nih.gov/21851967/
In vivo activity:
In this LPS-induced thrombosis rat model, the direct FXa inhibitor, edoxaban, significantly inhibited the hypercoagulation, the fibrin deposition in the liver, and the elevation of the liver damage parameters in a dose-dependent manner. Furthermore, edoxaban significantly reduced mortality caused by LPS. However, edoxaban did not suppressed the elevation of inflammatory cytokines and the kidney damage. Reference: J Thromb Thrombolysis. 2021 Feb 3 : 1–9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856452/
Solvent mg/mL mM
Solubility
DMSO 75.0 101.59
Water 1.0 1.35
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 738.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Hillarp A, Strandberg K, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Lindahl TL. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. Scand J Clin Lab Invest. 2018 Nov-Dec;78(7-8):575-583. doi: 10.1080/00365513.2018.1522664. Epub 2018 Oct 2. PMID: 30278787. 2. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012 Apr;129(4):e77-82. doi: 10.1016/j.thromres.2011.07.026. Epub 2011 Aug 17. PMID: 21851967. 3. Nagata N, Kawasumi M, Fujimura A, Ando H. Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats. TH Open. 2021 Apr 14;5(2):e107-e112. doi: 10.1055/s-0041-1725041. PMID: 33870074; PMCID: PMC8046513. 4. Morishima Y, Shibutani T, Noguchi K, Ito Y, Honda Y. Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats. J Thromb Thrombolysis. 2021 Feb 3:1–9. doi: 10.1007/s11239-021-02381-y. Epub ahead of print. PMID: 33534029; PMCID: PMC7856452.
In vitro protocol:
1. Hillarp A, Strandberg K, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Lindahl TL. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. Scand J Clin Lab Invest. 2018 Nov-Dec;78(7-8):575-583. doi: 10.1080/00365513.2018.1522664. Epub 2018 Oct 2. PMID: 30278787. 2. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012 Apr;129(4):e77-82. doi: 10.1016/j.thromres.2011.07.026. Epub 2011 Aug 17. PMID: 21851967.
In vivo protocol:
1. Nagata N, Kawasumi M, Fujimura A, Ando H. Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats. TH Open. 2021 Apr 14;5(2):e107-e112. doi: 10.1055/s-0041-1725041. PMID: 33870074; PMCID: PMC8046513. 2. Morishima Y, Shibutani T, Noguchi K, Ito Y, Honda Y. Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats. J Thromb Thrombolysis. 2021 Feb 3:1–9. doi: 10.1007/s11239-021-02381-y. Epub ahead of print. PMID: 33534029; PMCID: PMC7856452.
1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548805/ PubMed PMID: 31644112. 2: Cervantes CE, Merino JL, Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2019 Apr;17(4):319-330. doi: 10.1080/14779072.2019.1598263. Epub 2019 Mar 27. Review. PubMed PMID: 30897988. 3: Pharmacoeconomic Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535088/ PubMed PMID: 30540394. 4: CADTH Canadian Drug Expert Committee Final Recommendation: Edoxaban: (Lixiana — Servier Canada Inc.): Indication: Venous Thromboembolic Events [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK534995/ PubMed PMID: 30540393. 5: Clinical Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535077/ PubMed PMID: 30540391. 6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500740/ PubMed PMID: 29999799. 7: Linkins LA MD, MSc, FRCPC. Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism. BMJ Evid Based Med. 2018 Dec;23(6):230. doi: 10.1136/bmjebm-2018-111007. Epub 2018 Jun 29. Review. PubMed PMID: 29959155. 8: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK475920/ PubMed PMID: 29341555. 9: Institute for Quality and Efficiency in Health Care. Edoxaban -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Oct 28. Available from http://www.ncbi.nlm.nih.gov/books/NBK458399/ PubMed PMID: 29144699. 10: Hammwöhner M, Goette A. The safety of edoxaban for treating atrial fibrillation. Expert Opin Drug Saf. 2017 Nov;16(11):1295-1303. doi: 10.1080/14740338.2017.1372418. Epub 2017 Sep 18. Review. PubMed PMID: 28862063. 11: O'connor CT, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):725-739. doi: 10.1080/17425255.2017.1338274. Epub 2017 Jun 13. Review. PubMed PMID: 28571507. 12: Gibson CM, Finks SW. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape? Am J Med. 2017 Aug;130(8):900-906. doi: 10.1016/j.amjmed.2017.02.048. Epub 2017 Apr 6. Review. PubMed PMID: 28390791. 13: Scheen AJ, Lancellotti P. [Edoxaban (LIXIANA®) : new oral anticoagulant forthetreatment and secondary prevention of thromboembolic disease]. Rev Med Liege. 2016 Nov;71(11):517-524. Review. French. PubMed PMID: 28387109. 14: Weiss TW, Rohla M, Dieplinger B, Domanovits H, Fries D, Vosko MR, Gary T, Ay C. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper]. Wien Med Wochenschr. 2018 Apr;168(5-6):133-143. doi: 10.1007/s10354-017-0548-4. Epub 2017 Feb 24. Review. German. PubMed PMID: 28236004. 15: Curto A, Curto D, Sanchez J. Managing patients taking edoxaban in dentistry. J Clin Exp Dent. 2017 Feb 1;9(2):e308-e311. doi: 10.4317/jced.53431. eCollection 2017 Feb. Review. PubMed PMID: 28210454; PubMed Central PMCID: PMC5303336. 16: De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A, Patti G, Rossini R, Rubboli A, Schinco P, Agnelli G. Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. Adv Ther. 2017 Mar;34(3):620-637. doi: 10.1007/s12325-017-0488-9. Epub 2017 Feb 13. Review. PubMed PMID: 28194578; PubMed Central PMCID: PMC5350200. 17: Poulakos M, Walker JN, Baig U, David T. Edoxaban: A direct oral anticoagulant. Am J Health Syst Pharm. 2017 Feb 1;74(3):117-129. doi: 10.2146/ajhp150821. Review. PubMed PMID: 28122753. 18: Aspromonte N, Colivicchi F. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):113-122. Epub 2016 Nov 18. Review. PubMed PMID: 27819149. 19: Minguet J, Sims HM, Smith KH, Bramlage P. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Expert Rev Clin Pharmacol. 2017 Jan;10(1):5-15. doi: 10.1080/17512433.2016.1258301. Epub 2016 Nov 17. Review. Erratum in: Expert Rev Clin Pharmacol. 2017 Jan;10 (1):1. PubMed PMID: 27817212. 20: AlHajri L, Jabbari S, AlEmad H, AlMahri K, AlMahri M, AlKitbi N. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review. J Cardiovasc Pharmacol Ther. 2017 May;22(3):230-238. doi: 10.1177/1074248416675732. Epub 2016 Nov 2. Review. PubMed PMID: 27811198.

View History

AZD9291DA HCl salt

AZD9291DA HCl salt